ContentsValue Creation Story
2	Vision/Corporate Message/Corporate Philosophy
4

Importance of Female Healthcare and Social Issues

6

History of Value Creation

8	At a Glance
10	Value Creation Process
12 	Message from the President
16 	Material Issues

Explanation of Strategy
18	ASKA Pharmaceutical Holdings’ Medium-Term

Management Plan 2025
20

Financial and Capital Strategy

22

Overview of ASKA Pharmaceutical Holdings

24

Business Conditions  24 ASKA Pharmaceutical  30 ASKA Animal Health  32 ASKA Pharma Medical

Foundation for Value Creation
34

Human Resources

40

R&D for Sustainable Growth42

Reliability Assurance/Sales

43

Activities of Health Lab Mint+ for Women’s health

44

Messages from Outside Directors

46	Corporate Governance/Compliance/Risk Management
52

Board Members and Corporate Officers

54

Environment

Data Section
56

11-Year Summary of Consolidated Financial Results

58

Stakeholder Communication – Editorial Postscript

59

Company Information/Shareholder Information

Referenced Guidelines and Frameworks• GRI Standards• IFRS Foundation Integrated Reporting Framework• ISO 26000 Guidance on Social Responsibility• Ministry of Economy, Trade and Industry, Guidance for Integrated Corporate Disclosureand Company-Investor Dialogue for Collaborative Value Creation• Ministry of the Environment, Environmental Reporting Guidelines (2018)• Recommendations of Task Force on Climate-related Financial Disclosures (TCFD)(Final Report), and others

Reported Matters
Editorial Policy
ASKA Pharmaceutical Holdings Co., Ltd. issues the ASKA HD Report as an Integrated Report (Annual Report) to communicate
messages from management on the Company’s management strategies and priority issues. It also includes information on theCompany’s environmental, social and governance (ESG) initiatives and finances. Information based on the seven core principlesof ISO 26000, the international standard for social responsibility, and its classifications, is presented on the Company’s website.
ASKA HD REPORT 2023 introduces the initiatives of ASKA Pharmaceutical, ASKA Animal Health and ASKA Pharma Medical
under the theme of clarifying and promoting a better understanding of the strengths of ASKA Pharmaceutical Holdings.
In producing this report, we narrowed down the most important information, based on the opinions and inquiries of ourstakeholders. We hope this report will help promote dialogue with our stakeholders.

• Period: April 1, 2022 to March 31, 2023 (includes some information from outside the period)• Scope: ASKA Pharmaceutical Holdings Co., Ltd. and Group companies
Note: In principle, this report covers the activities of the ASKA Pharmaceutical Holdings Group. However, when activities and data are for
ASKA Pharmaceutical Co., Ltd. (non-consolidated), “ASKA Pharmaceutical” is indicated.

Note on Forward-Looking Statements in This Report
Information on the Group’s business outlook and other forward-looking statements presented in this report are based on thejudgment of the Group’s management, which relies on various information at the time of publication. Actual results may differ
significantly from the outlook presented due to changes in market trends, economic conditions or other factors.
ASKA HD REPORT 2023

1